# Multi-Cancer Early Detection Market Size, Share & Growth 2026–2035

> The Global Multi-Cancer Early Detection market was valued at USD 1,264.8 Mn in 2025 and is projected to reach USD 5,517.4 Mn by 2035, a 15.87% CAGR over 2026–2035, according to Vectomat Insights. North America leads with a 37.2% share, liquid biopsy holds 47.0% of revenue, and lung cancer is the largest and fastest-growing cancer-type segment.

- Publisher: Vectomat Insights
- Report code: VMI-1-3-58656
- Published: 2026-10-29
- Canonical URL: https://www.vectomatinsights.com/report/multi-cancer-early-detection-market
- Base year 2025: USD 1,264.8 Mn
- Forecast 2035: USD 5,517.4 Mn
- CAGR 2026–2035: 15.87%

## Key insights

- The market is projected to grow from USD 1,264.8 Mn in 2025 to USD 5,517.4 Mn by 2035 at a 15.87% CAGR, according to Vectomat Insights.
- Liquid biopsy is the dominant technology at 47.0% of 2025 revenue (USD 594.3 Mn) and is also the fastest-growing, at a 19.62% CAGR through 2035.
- Lung cancer is the leading cancer-type segment at 22.0% of 2025 revenue (USD 278.7 Mn) and compounds fastest at 21.51% a year, because no blood-based alternative to low-dose CT reaches most eligible smokers today.
- Blood-based tests account for 69.3% of 2025 revenue (USD 877.0 Mn), while tissue-based confirmatory testing grows fastest at a 21.14% CAGR as positive screens trigger diagnostic workups.
- Diagnostic laboratories are the largest end user at 38.8% of revenue, since nearly every MCED test is run as a laboratory-developed test in a CLIA-certified central lab; academic and research institutes grow fastest at 23.11%.
- North America leads with a 37.2% share (USD 470.5 Mn), and the U.S. alone was worth USD 395.5 Mn in 2025.
- Asia Pacific is the fastest-growing region, led by South Korea at a 17.9% CAGR and Japan at 15.9%.
- Consolidation is accelerating: Abbott closed its acquisition of Exact Sciences in March 2026, and Freenome listed on Nasdaq in July 2026 with about USD 310 Mn in proceeds.
- The February 2026 Nancy Gardner Sewell Medicare MCED Act creates a Medicare payment pathway once a test wins FDA approval — the single largest reimbursement catalyst inside the 2026–2035 forecast horizon.

## Figures

![Multi-cancer early detection market size — USD 1,264.8 Mn (2025) to USD 5,517.4 Mn (2035) | Vectomat Insights](https://vectomat-media-prod.tor1.cdn.digitaloceanspaces.com/reports/multi-cancer-early-detection-market/bb5bac58f9fa9f86/multi-cancer-early-detection-market-size-vmi.png) — The Global Multi-Cancer Early Detection market grows from USD 1,264.8 Mn in 2025 to USD 5,517.4 Mn by 2035, a 15.87% CAGR. Source: Vectomat Insights, Multi-Cancer Early Detection Market Report.
![Multi-cancer early detection market DROC — FDA momentum and Medicare pathway vs. evidence gaps | Vectomat Insights](https://vectomat-media-prod.tor1.cdn.digitaloceanspaces.com/reports/multi-cancer-early-detection-market/bb5bac58f9fa9f86/multi-cancer-early-detection-market-droc-vmi.png) — Regulatory momentum and a new Medicare pathway drive the market, while unproven mortality benefit and self-pay pricing restrain it. Source: Vectomat Insights, Multi-Cancer Early Detection Market Report.
![Multi-cancer early detection market share by region — North America leads at 37.2% in 2025 | Vectomat Insights](https://vectomat-media-prod.tor1.cdn.digitaloceanspaces.com/reports/multi-cancer-early-detection-market/bb5bac58f9fa9f86/multi-cancer-early-detection-market-regional-share-vmi.png) — North America leads the Global Multi-Cancer Early Detection market with a 37.2% share in 2025, while Asia Pacific grows fastest. Source: Vectomat Insights, Multi-Cancer Early Detection Market Report.
![Multi-cancer early detection market segmentation — liquid biopsy, lung cancer and blood-based tests lead | Vectomat Insights](https://vectomat-media-prod.tor1.cdn.digitaloceanspaces.com/reports/multi-cancer-early-detection-market/bb5bac58f9fa9f86/multi-cancer-early-detection-market-segments-vmi.png) — Liquid biopsy, lung cancer, blood-based sampling and diagnostic laboratories lead their dimensions in 2025. Source: Vectomat Insights, Multi-Cancer Early Detection Market Report.
![Multi-cancer early detection market share by technology — liquid biopsy 47.0% in 2025 | Vectomat Insights](https://vectomat-media-prod.tor1.cdn.digitaloceanspaces.com/reports/multi-cancer-early-detection-market/bb5bac58f9fa9f86/multi-cancer-early-detection-market-technology-share-vmi.png) — Liquid biopsy holds 47.0% of 2025 revenue, the largest technology share. Source: Vectomat Insights, Multi-Cancer Early Detection Market Report.
![Multi-cancer early detection market share by end user — diagnostic laboratories 38.8% | Vectomat Insights](https://vectomat-media-prod.tor1.cdn.digitaloceanspaces.com/reports/multi-cancer-early-detection-market/bb5bac58f9fa9f86/multi-cancer-early-detection-market-end-user-share-vmi.png) — Diagnostic laboratories account for 38.8% of 2025 revenue, the largest end-user share. Source: Vectomat Insights, Multi-Cancer Early Detection Market Report.
![Multi-cancer early detection technology mix by region — liquid biopsy leads in North America at 52.0% | Vectomat Insights](https://vectomat-media-prod.tor1.cdn.digitaloceanspaces.com/reports/multi-cancer-early-detection-market/bb5bac58f9fa9f86/multi-cancer-early-detection-market-regional-segments-vmi.png) — Liquid biopsy's share is highest in North America at 52.0%, while proteomic tests take a larger slice of the Asia Pacific mix. Source: Vectomat Insights, Multi-Cancer Early Detection Market Report.
![Multi-cancer early detection competitive positioning — GRAIL, Exact Sciences and Guardant Health lead | Vectomat Insights](https://vectomat-media-prod.tor1.cdn.digitaloceanspaces.com/reports/multi-cancer-early-detection-market/bb5bac58f9fa9f86/multi-cancer-early-detection-market-competitive-landscape-vmi.png) — GRAIL, Exact Sciences and Guardant Health combine the deepest test volume with the most advanced regulatory and payer readiness. Source: Vectomat Insights, Multi-Cancer Early Detection Market Report.
![Multi-cancer early detection market at a glance — USD 1,264.8 Mn (2025) to USD 5,517.4 Mn at 15.87% CAGR | Vectomat Insights](https://vectomat-media-prod.tor1.cdn.digitaloceanspaces.com/reports/multi-cancer-early-detection-market/bb5bac58f9fa9f86/multi-cancer-early-detection-market-key-numbers-vmi.png) — Key numbers for the Global Multi-Cancer Early Detection market: size, CAGR, leading segments, regions and companies. Source: Vectomat Insights, Multi-Cancer Early Detection Market Report.
![United States multi-cancer early detection market — USD 395.5 Mn (2025) to USD 1,586.2 Mn (2035) | Vectomat Insights](https://vectomat-media-prod.tor1.cdn.digitaloceanspaces.com/reports/multi-cancer-early-detection-market/bb5bac58f9fa9f86/multi-cancer-early-detection-market-united-states-snapshot-vmi.png) — The United States market grows from USD 395.5 Mn in 2025 to about USD 1,586.2 Mn by 2035 at a 14.9% CAGR. Source: Vectomat Insights, Multi-Cancer Early Detection Market Report.
![Germany multi-cancer early detection market — USD 94.2 Mn (2025) to USD 355.4 Mn (2035) | Vectomat Insights](https://vectomat-media-prod.tor1.cdn.digitaloceanspaces.com/reports/multi-cancer-early-detection-market/bb5bac58f9fa9f86/multi-cancer-early-detection-market-germany-snapshot-vmi.png) — The Germany market grows from USD 94.2 Mn in 2025 to about USD 355.4 Mn by 2035 at a 14.2% CAGR. Source: Vectomat Insights, Multi-Cancer Early Detection Market Report.
![Japan multi-cancer early detection market — USD 98.8 Mn (2025) to USD 432.1 Mn (2035) | Vectomat Insights](https://vectomat-media-prod.tor1.cdn.digitaloceanspaces.com/reports/multi-cancer-early-detection-market/bb5bac58f9fa9f86/multi-cancer-early-detection-market-japan-snapshot-vmi.png) — The Japan market grows from USD 98.8 Mn in 2025 to about USD 432.1 Mn by 2035 at a 15.9% CAGR. Source: Vectomat Insights, Multi-Cancer Early Detection Market Report.

## Market size (USD million)

| Year | Value |
|---|---|
| 2023 | 973.1 |
| 2024 | 1,109.5 |
| 2025 | 1,264.8 |

## Share by Technology (2025)

| Segment | Share | USD Mn |
|---|---|---|
| Liquid Biopsy | 47% | 594.3 |
| Genomic Analysis | 13.4% | 169.5 |
| Epigenetic & Methylation Analysis | 12.7% | 161.0 |
| Proteomic Analysis | 12.8% | 161.3 |
| Multi-Omics Platforms | 14.1% | 178.7 |

## Share by Cancer Type (2025)

| Segment | Share | USD Mn |
|---|---|---|
| Lung Cancer | 22% | 278.7 |
| Colorectal Cancer | 16% | 202.4 |
| Pancreatic Cancer | 16.7% | 211.5 |
| Liver Cancer | 15.1% | 190.7 |
| Ovarian Cancer | 15.2% | 192.7 |
| Other Cancers | 14.9% | 188.8 |

## Share by Sample Type (2025)

| Segment | Share | USD Mn |
|---|---|---|
| Blood-Based | 69.3% | 877.0 |
| Tissue-Based | 10.1% | 127.8 |
| Urine-Based | 11% | 139.5 |
| Other Sample Types | 9.5% | 120.5 |

## Share by End User (2025)

| Segment | Share | USD Mn |
|---|---|---|
| Diagnostic Laboratories | 38.8% | 490.4 |
| Hospitals & Diagnostic Centers | 19.7% | 249.2 |
| Academic & Research Institutes | 19.8% | 250.5 |
| Physician Offices | 21.7% | 274.7 |

## Regional share

| Region | Share | USD Mn |
|---|---|---|
| North America | 37.2% | 470.5 |
| Europe | 25.5% | 322.5 |
| Asia Pacific | 25.7% | 325.1 |
| Latin America | 5.3% | 67.0 |
| The Middle East | 3.1% | 39.2 |
| Africa | 3.2% | 40.5 |

## Key companies

- GRAIL (U.S.): Galleri methylation-based MCED blood test
- Exact Sciences (U.S.): Cancerguard multi-biomarker blood test; Cologuard
- Guardant Health (U.S.): Shield blood tests (CRC and MCD)
- Freenome (U.S.): Multiomics blood tests for early cancer detection
- Natera (U.S.): Cell-free DNA testing and molecular residual disease
- Illumina (U.S.): Sequencing and proteomic platforms
- Quest Diagnostics (U.S.): National clinical laboratory network
- DELFI Diagnostics (U.S.): Fragmentomics blood tests (FirstLook Lung)
- Harbinger Health (U.S.): Blood-based cancer detection test suite
- Burning Rock Biotech (China): NGS oncology testing; OverC multi-cancer test
- Gene Solutions (Vietnam): SPOT-MAS multi-cancer screening tests
- GC Genome (South Korea): cfDNA cancer screening tests
- Mirxes (Singapore): microRNA blood tests (GASTROClear)
- Craif (Japan): Urine-based miSignal cancer risk test

## FAQs

### How big is the Multi-Cancer Early Detection market in 2025?

Vectomat Insights sizes the global market at USD 1,264.8 Mn in 2025, up from USD 973.1 Mn in 2023. It is projected to reach USD 5,517.4 Mn by 2035 at a 15.87% CAGR. Liquid biopsy alone generated USD 594.3 Mn of 2025 revenue, and blood-based sampling accounted for USD 877.0 Mn. North America contributed the largest regional slice at USD 470.5 Mn, and Asia Pacific added the fastest growth, according to Vectomat Insights.

### Which technology segment leads the Multi-Cancer Early Detection market?

Liquid biopsy leads with 47.0% of 2025 revenue and is also the fastest-growing technology, compounding at 19.62% to USD 3,565.2 Mn by 2035. Genomic analysis grows at 16.05%, while proteomic analysis and multi-omics platforms expand more slowly as their markers are folded into blood-based panels such as Exact Sciences' Cancerguard. By 2035, liquid biopsy is expected to represent nearly two-thirds of total market revenue, according to Vectomat Insights.

### Which cancer type generates the most multi-cancer screening revenue?

Lung cancer generates the most revenue, at 22.0% of the 2025 total (USD 278.7 Mn), and grows fastest at a 21.51% CAGR to USD 1,955.0 Mn by 2035. Pancreatic cancer follows at 16.7% and colorectal at 16.0%. Lung leads because low-dose CT screening still reaches only a minority of eligible adults, so blood tests act as an on-ramp to imaging for smokers and former smokers, according to Vectomat Insights.

### Which region is growing fastest in the Multi-Cancer Early Detection market?

Asia Pacific is the fastest-growing region and holds 25.7% of 2025 revenue (USD 325.1 Mn). South Korea is the fastest-growing tracked country at a 17.9% CAGR, and Japan, at USD 98.8 Mn, is forecast to reach about USD 432.1 Mn by 2035. Insurer partnerships, such as Guardant Health's Shield MCD launch with Manulife, and local developers selling lower-priced tests drive volume, according to Vectomat Insights.

### What is restraining the Multi-Cancer Early Detection market?

Two factors restrain growth. No trial has yet shown that multi-cancer screening reduces cancer deaths, and NHS-Galleri missed its primary stage III–IV endpoint in 2026 even though stage IV diagnoses fell. Most U.S. testing is also self-pay at prices near USD 949, with follow-up imaging and biopsy adding cost. Until Medicare coverage begins under the 2026 law, these factors keep uptake concentrated among higher-income adults, according to Vectomat Insights.

### What research methodology does Vectomat Insights use for this report?

The report combines a bottom-up build of developer revenues with a volume-based estimate of tests performed, benchmarked against prices across self-pay, employer and reimbursed channels. Primary interviews with laboratory directors, physicians and payers are paired with SEC filings, FDA records and peer-reviewed trials, then reconciled to the USD 1,264.8 Mn base-year total and checked against regional and country totals, according to Vectomat Insights.

### Does the report include country-level and company-level data?

Yes. The report covers 35+ countries across six regions, including snapshots for the U.S. (USD 395.5 Mn in 2025), Germany (USD 94.2 Mn) and Japan (USD 98.8 Mn), with forecasts to 2035. It also profiles 14 companies, from GRAIL and Guardant Health to Gene Solutions and Craif, covering primary focus, strategy and dated recent actions such as regulatory milestones, launches and acquisitions, according to Vectomat Insights.

Cite as: Vectomat Insights (2026). Multi-Cancer Early Detection Market Report. https://www.vectomatinsights.com/report/multi-cancer-early-detection-market